A new study finds that elevated levels of Lp(a) may increase the risk of death from cardiovascular disease in some patie ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Very high Lp(a) also correlated with higher risks of ischemic stroke and cardiovascular mortality in the Women’s Health Study ...

Please provide your email address to receive an email when new articles are posted on . About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex ...